McAndrews, Held & Malloy Secures Victory for Abbott Laboratories
McAndrews, Held & Malloy announced today that it has secured a victory for its clients, Abbott Laboratories and Abbott Cardiovascular Systems, in a case involving drug-eluting coronary stent systems used in the treatment of coronary artery disease.
In 2008, Cordis Corporation and Pfizer Inc. unit Wyeth Pharmaceuticals Inc. filed a lawsuit against Abbott and other defendants for infringement of multiple patents directed to methods for treating and preventing restenosis following angioplasty. On January 19, 2012, shortly before the trial was to begin, the U.S. District Court for the District of New Jersey granted the defendants’ motion for summary judgment of invalidity. The Court ruled that the patents were invalid because they failed to meet the written description and enablement requirements.
Earlier last year, McAndrews represented Abbott in another lawsuit involving four other Cordis and Wyeth patents relating to drug-eluting stent systems. In that case, the Federal Circuit affirmed a summary judgment ruling that all four patents were invalid as a matter of law.
Edward A. Mas II and multiple McAndrews attorneys represented Abbott.